Biocryst pharmaceuticals inc (BCRX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenues

4,823

39,725

1,775

1,448

5,887

2,729

1,454

12,494

3,976

3,890

8,760

3,099

9,437

8,983

7,763

4,787

4,820

4,602

10,987

25,842

6,826

5,446

3,238

1,466

3,458

10,567

2,389

821

3,554

4,101

5,761

4,210

12,221

5,224

5,249

3,735

5,435

12,000

7,616

Expenses
Cost of product sales

-

2,327

0

0

1,399

-

-

-

-

-

1,142

-

-

-

0

-

-

7

1,346

0

15

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

29,867

26,774

25,120

27,681

27,493

23,431

22,006

21,010

18,441

16,924

17,509

15,759

16,770

12,158

14,105

14,166

20,579

19,047

20,067

16,524

17,120

18,510

13,036

11,067

9,183

15,224

7,977

11,527

7,215

8,786

12,072

12,777

15,525

14,303

15,101

14,442

13,403

19,197

14,737

Selling, general and administrative

15,865

10,489

11,735

8,659

6,238

4,490

7,923

9,492

7,609

4,698

3,343

2,834

3,058

2,561

2,756

2,724

3,212

2,721

2,731

3,534

4,061

2,048

1,812

2,013

1,588

1,660

1,337

1,432

1,578

4,233

1,591

1,609

1,697

1,961

2,953

3,536

3,531

3,793

3,209

Royalty

69

244

18

26

87

70

18

243

140

129

115

22

294

155

143

27

77

21

5

442

60

43

0

5

73

17

0

4

77

-

114

-

-

-

-

-

-

-

-

Total operating expenses

45,801

39,834

36,873

36,366

35,217

27,991

29,947

30,745

26,190

21,751

22,109

18,615

20,122

17,171

17,004

16,917

23,868

21,796

24,149

20,500

21,256

20,602

14,848

13,085

10,844

16,901

9,314

12,963

8,870

14,796

13,777

14,386

17,222

16,264

18,054

17,978

16,934

22,990

17,946

Loss from operations

-40,978

-109

-35,098

-34,918

-29,330

-25,262

-28,493

-18,251

-22,214

-17,861

-13,349

-15,516

-10,685

-8,188

-9,241

-12,130

-19,048

-17,194

-13,162

5,342

-14,430

-15,156

-11,610

-11,619

-7,386

-6,334

-6,925

-12,142

-5,316

-10,695

-8,016

-10,176

-5,001

-11,040

-12,805

-14,243

-11,499

-10,990

-10,330

Interest and other income

6,446

388

402

547

596

686

611

493

462

478

225

203

109

98

109

147

439

168

134

116

117

43

14

19

17

21

18

21

33

40

54

57

71

83

92

136

102

126

137

Interest expense

3,047

3,087

3,044

3,035

2,726

2,414

2,346

2,195

2,221

2,231

2,140

2,094

2,100

2,131

1,465

1,421

1,470

1,338

1,241

1,306

1,315

1,314

1,217

1,225

1,242

1,242

1,191

1,165

1,180

1,180

1,166

1,160

1,160

1,160

1,160

1,166

288

-

-

(Loss) gain on foreign currency derivative

-20

186

148

-223

406

-442

631

1,507

-1,804

71

130

521

-1,543

5,718

-931

-2,877

-2,753

229

-352

749

464

4,755

4,082

-1,824

-1,526

2,126

97

1,114

1,957

782

-572

-997

38

-1,074

-586

-998

-1,342

-

-

Net loss

-37,599

-2,622

-37,592

-37,629

-31,054

-27,432

-29,597

-18,446

-25,777

-19,543

-15,134

-16,886

-14,219

-4,503

-11,528

-16,281

-22,832

-18,135

-14,621

4,901

-15,164

-11,672

-8,731

-14,649

-10,137

-5,429

-8,001

-12,172

-4,506

-11,053

-9,700

-12,276

-6,052

-13,191

-14,459

-16,271

-13,027

-10,864

-10,193

Weighted average shares outstanding (in Shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

59,589

-

57,124

53,468

51,073

50,912

50,661

49,218

47,105

-

45,178

45,111

-

44,884

44,517

Unrealized (loss) gain on available for sale investments

-25

-21

19

130

208

113

42

24

-233

-226

-2

-12

9

-34

-24

-2

254

-205

91

-102

140

-132

-1

1

-2

2

-4

-9

-12

-13

0

-9

9

-8

-42

9

-24

-

-

Net comprehensive loss

-37,624

-2,643

-37,573

-37,499

-30,846

-27,319

-29,555

-18,422

-26,010

-19,769

-15,136

-16,898

-14,210

-4,537

-11,552

-16,283

-22,578

-18,340

-14,530

4,799

-15,024

-11,804

-8,732

-14,648

-10,139

-5,427

-8,005

-12,181

-4,518

-11,066

-9,700

-12,285

-6,043

-13,199

-14,501

-16,262

-13,051

-

-

Basic and diluted net loss per common share (in dollars per share)

-0.24

0.02

-0.34

-0.34

-0.28

-0.25

-0.28

-0.19

-0.26

-0.20

-0.18

-0.21

-0.19

-0.06

-0.16

-0.22

-0.31

-

-0.20

-

-0.21

-

-0.12

-

-0.17

-0.09

-0.14

-0.23

-0.09

-0.22

-0.19

-0.25

-0.13

-0.29

-0.32

-0.36

-0.29

-0.24

-0.23

Basic net (loss) income per common share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.07

-

-

-

-0.23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted net (loss) income per common share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.06

-

-

-

-0.23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares outstanding, basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

72,642

-

-

-

63,647

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares outstanding (in shares)

154,156

131,479

110,416

110,338

110,167

109,951

105,410

98,787

98,592

98,649

83,570

80,418

75,167

73,766

73,734

73,695

73,601

69,241

73,262

76,760

72,341

-

71,801

63,647

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product [Member]
Revenues

218

15,519

335

0

1,679

-

-

-

-

-

1,501

-

-

-

0

-

-

55

5,699

0

537

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalty [Member]
Revenues

1,945

2,777

508

696

2,322

1,775

523

142

3,661

3,291

442

489

6,321

3,662

3,501

629

1,890

610

126

132

1,518

1,074

5

125

1,821

520

8

110

1,924

469

2,848

0

0

-

-

-

-

-

-

Collaborative and Other Research and Development [Member]
Revenues

2,660

21,429

932

752

1,886

954

931

12,352

315

599

6,817

2,610

3,116

3,052

4,262

4,158

2,930

3,937

5,162

25,710

4,771

4,339

3,233

1,341

1,637

10,047

2,381

711

1,630

3,632

2,913

4,210

12,221

5,224

5,249

3,735

5,435

12,000

7,616